Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of twice-daily exenatide in type 2 diabetes mellitus
2004-000573-54Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Summary of adverse events. Started Feb 2005; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000573-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000573-54.